menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gadolinium Ethoxybenzyl Dtpa","moa":"MRI contrast","graph1":"Undisclosed","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Bayer AG | Bracco | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gadolinium Ethoxybenzyl Dtpa","moa":"MRI contrast","graph1":"Neurology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Bayer AG | Bracco | GE Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Bayer AG | Bracco | GE Healthcare"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bracco | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gadolinium Ethoxybenzyl Dtpa","moa":"MRI contrast","graph1":"Oncology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Bracco | National Cancer Institute","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Bracco | National Cancer Institute"},{"orgOrder":0,"company":"Slawa Cwajna","sponsor":"Nova Scotia Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gadolinium Ethoxybenzyl Dtpa","moa":"MRI contrast","graph1":"Oncology","graph2":"Phase IV","graph3":"Slawa Cwajna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slawa Cwajna \/ Nova Scotia Health Authority","highestDevelopmentStatusID":"11","companyTruncated":"Slawa Cwajna \/ Nova Scotia Health Authority"}]

    Find Clinical Drug Pipeline Developments & Deals for Gadolinium Ethoxybenzyl Dtpa

    Menu

    Gadolinium Ethoxybenzyl Dtpa

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Colorado, Denver

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Colorado, Denver

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Bracco | National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

                            Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Oligometastatic Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Bracco | National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GUERBET

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GUERBET

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Bayer AG | Bracco | GE Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magneti...

                            Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motor Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2020

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Bayer AG | Bracco | GE Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Slawa Cwajna

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Slawa Cwajna

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Nova Scotia Health Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium

                            Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2017

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Nova Scotia Health Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bayer AG

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/...

                            Details : Gadoxetate Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2014

                            Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth